STOCK TITAN

Oric Pharmaceuticals, Inc. - ORIC STOCK NEWS

Welcome to our dedicated news page for Oric Pharmaceuticals (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oric Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oric Pharmaceuticals 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences
Oric Pharmaceuticals, Inc.

Nasdaq:ORIC

ORIC Rankings

ORIC Stock Data

595.34M
37.08M
9.53%
88.37%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About ORIC

oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.